非营利性生物技术公司Xeno将收购ESSA Pharma，由XOMA Royalty Corporation以全现金交易支持-动脉网

ESSA Pharma Inc. Announces Definitive Agreement to be Acquired by XenoTherapeutics, Inc., Backed by XOMA Royalty Corporation in All-Cash Transaction

CISION 等信源发布 2025-07-14 20:00



可切换为仅中文







SOUTH SAN FRANCISCO, Calif.

加利福尼亚州南旧金山

and

和

VANCOUVER, BC

加拿大温哥华

and

和

BOSTON

波士顿

and

和

EMERYVILLE, Calif.

加利福尼亚州埃默里维尔

，

July 14, 2025

2025年7月14日

/PRNewswire/ -- ESSA Pharma Inc. ('ESSA,' or the 'Company') (NASDAQ:

/PRNewswire/ -- ESSA制药公司（“ESSA”或“公司”）（纳斯达克：

EPIX

) today announced that it has entered into a definitive agreement (the 'Business Combination Agreement') with XenoTherapeutics, Inc. ('Xeno'), a non-profit biotechnology company, under which Xeno will acquire (the 'Transaction') all of the issued and outstanding common shares of ESSA (the 'Common Shares').

）今天宣布，已与非营利生物技术公司XenoTherapeutics, Inc.（“Xeno”）达成最终协议（“业务合并协议”），根据该协议，Xeno将收购ESSA所有已发行和流通的普通股（“普通股”）。

XOMA Royalty Corporation ('XOMA Royalty') (NASDAQ: .

XOMA特许权公司（“XOMA特许权”）（纳斯达克：。

XOMA

), the biotechnology royalty aggregator, is acting as the structuring agent and will provide financing to Xeno for this Transaction.

)，这家生物技术专利费聚合商，担任结构设计代理，并将为这项交易向Xeno提供融资。

Under the terms of the Business Combination Agreement, ESSA shareholders will receive a cash payment per Common Share that will be determined based upon ESSA's cash balance at closing after deducting certain transaction costs, a reserve for liabilities and legal expenses, and a transaction fee (the 'Final Cash Amount').

根据业务合并协议的条款，ESSA股东将获得每股普通股的现金支付，该金额将根据在扣除某些交易成本、负债和法律费用的准备金以及交易费用后，ESSA在交割时的现金余额来确定（“最终现金金额”）。

In addition, each ESSA shareholder will also receive one non-transferable contingent value right (each, a 'CVR') for each Common Share that entitles the holder to receive a pro rata portion of up to .

此外，每位ESSA股东还将获得每份普通股对应的一个不可转让的或有价值权（每个“CVR”），该权利赋予持有人按比例获得最高额度的权利。

US$2,950,000

2,950,000美元

(up to

直到

US$0.06

0.06美元

per CVR) within 18 months following the close of the Transaction.

根据CVR，在交易完成后的18个月内。

To expedite the distribution of cash to ESSA shareholders, ESSA will also apply to the Supreme Court of

为了加快现金分配给ESSA股东的速度，ESSA还将向最高法院申请

British Columbia

不列颠哥伦比亚省

for an order authorizing it to make an initial cash distribution to ESSA shareholders prior to the closing of the Transaction. In total, with the initial cash distribution, if authorized, and the cash payable upon closing of the Transaction, each ESSA shareholder is currently estimated to receive approximately .

授权其在交易完成前向ESSA股东进行初步现金分配的指令。总计，如果获得授权，通过初步现金分配以及交易完成时应付的现金，目前预计每位ESSA股东将收到大约。

US$1.91

1.91美元

per Common Share, exclusive of any payments received pursuant to the CVR. The date of the applications will be announced by further press release. Inquiries related to such applications can be directed to ESSA's counsel, Blake, Cassels & Graydon LLP, 1133 Melville Street, Suite 3500, The Stack,

每股普通股，不包括根据CVR收到的任何款项。申请日期将通过进一步的新闻发布公布。有关此类申请的查询可向ESSA的法律顾问布莱克、卡塞尔和格雷登律师事务所咨询，地址：1133梅尔维尔街，3500室，The Stack。

Vancouver, BC

不列颠哥伦比亚省温哥华

V6E 4E5 attention:

V6E 4E5 注意：

Alexandra Luchenko

亚历山德拉·卢琴科

, or by email to

，或者通过电子邮件发送至

alexandra.luchenko@blakes.com

。

'After conducting a comprehensive review of the opportunities available to ESSA and considering the communications received from our shareholders, the ESSA Board of Directors has unanimously concluded that entering into this agreement with Xeno and XOMA Royalty is in the best interest of the Company and maximizes value for our shareholders as the Company proceeds with its plans to discontinue operations and wind-down its business,' said .

“在对ESSA可利用的机会进行全面审查并考虑了来自我们股东的反馈后，ESSA董事会一致认为，与Xeno和XOMA Royalty达成该协议符合公司的最佳利益，并且在公司继续推进停止运营和逐步结束业务的计划过程中，能够为我们的股东实现价值最大化。”

David Parkinson

大卫·帕金森

, M.D., President and CEO of ESSA. 'This Transaction delivers cash value to shareholders in an expedited timeframe, with less complexity and value risk when compared to a liquidation, and thus delivers more certain value to shareholders.'

，ESSA的总裁兼首席执行官M.D.表示：“此交易相比清算，能在更短的时间内为股东带来现金价值，且复杂性更低，价值风险更小，从而为股东提供更为确定的价值。”

Transaction Details

交易明细

The Transaction will be implemented by way of a court-approved plan of arrangement under the

该交易将通过法院批准的安排计划实施，

Business Corporations Act

商业公司法

(

British Columbia

不列颠哥伦比亚省

) and will require approval of at least: (i) 66⅔% of the votes cast by ESSA shareholders; (ii) 66⅔% of the votes cast by ESSA securityholders (including holders of ESSA options and pre-funded warrants), voting together as a single class; and (iii) a majority of the votes cast by ESSA shareholders excluding votes held by certain 'interested parties' required to be excluded by Multilateral Instrument 61-101, at a special meeting to be held to consider the Transaction (the 'Special Meeting').

）并且需要至少获得以下批准：(i) ESSA股东投票的66⅔%；(ii) ESSA证券持有人（包括ESSA期权和预融资权证持有人）投票的66⅔%，作为一个单一类别共同投票；以及(iii) 排除某些“利益相关方”持有的票数后的ESSA股东投票的多数，这些“利益相关方”的票数根据多边协议61-101要求排除，在为审议该交易而召开的特别会议（“特别会议”）上进行表决。

In addition to approval by ESSA securityholders, the Transaction is also subject to receipt of court approval, and other customary conditions. The Transaction is expected to close in the second half of 2025..

除需获得ESSA股东的批准外，该交易还需获得法院的批准及其他惯例条件。预计该交易将于2025年下半年完成。

The Business Combination Agreement provides for customary deal-protection provisions, including a non-solicitation covenant on the part of the Company and a right for Xeno to match any Superior Proposal (each as defined in the Business Combination Agreement). The Business Combination Agreement includes a termination fee of .

业务合并协议包含了惯例的交易保护条款，包括公司的不招揽承诺以及Xeno对任何更优提案（均在业务合并协议中定义）的匹配权。业务合并协议包含终止费用。

US$2

2美元

.5 million, payable by the Company under certain circumstances, including in connection with the Company's entry into an agreement with respect to a Superior Proposal. The directors and senior officers of the Company, owning in aggregate approximately 2.23% of the outstanding shares of Common Shares, have entered into voting and support agreements, pursuant to which they have agreed to vote all of the securities beneficially owned by them in favor of the Transaction..

50万美元，在特定情况下由公司支付，包括与公司就更优提案达成协议的情况。公司董事及高级管理人员合计持有约2.23%的已发行普通股，并已签署投票和支持协议，根据该协议，他们同意将其所拥有的所有证券投票支持本次交易。

ESSA Board of Directors and Transaction Committee Recommendations

ESSA董事会和交易委员会建议

A transaction committee composed entirely of independent directors of the Company (the 'Transaction Committee') unanimously recommended entering into the Business Combination Agreement to the board of directors of ESSA (the 'Board'). The Board has evaluated the Business Combination Agreement with the Company's management, legal and financial advisors and, following the receipt and review of the unanimous recommendation from the Transaction Committee and the opinion of the Transaction Committee's financial advisors, the Board has unanimously approved the Transaction and determined that the Transaction is in the best interest of the Company.

由公司全体独立董事组成的交易委员会（“交易委员会”）一致建议ESSA董事会（“董事会”）签署业务合并协议。董事会在与公司的管理层、法律顾问和财务顾问评估了业务合并协议后，并在收到并审阅了交易委员会的一致建议及交易委员会财务顾问的意见后，一致批准了该交易，并认定该交易符合公司的最佳利益。

The Board has resolved to recommend that the Company's securityholders vote in favor of the Transaction, subject to the terms and conditions contained in the Business Combination Agreement..

董事会已决定建议公司的证券持有人投票支持该交易，但须遵守业务合并协议中包含的条款和条件。

Advisors

顾问

Leerink Partners is serving as the exclusive financial advisor to ESSA and Blake, Cassels & Graydon LLP and Skadden, Arps, Slate, Meagher & Flom LLP are serving as ESSA's Canadian legal counsel and U.S. legal counsel, respectively.

Leerink Partners 担任 ESSA 的独家财务顾问，Blake, Cassels & Graydon LLP 和 Skadden, Arps, Slate, Meagher & Flom LLP 分别担任 ESSA 的加拿大法律顾问和美国法律顾问。

Stikeman Elliott LLP and Gibson, Dunn & Crutcher LLP are serving as XOMA Royalty's Canadian legal counsel and U.S. legal counsel, respectively.

史蒂克曼·艾略特律师事务所和吉布森、邓恩与克拉彻律师事务所分别担任XOMA Royalty的加拿大法律顾问和美国法律顾问。

About ESSA Pharma Inc.

关于ESSA制药公司

ESSA is a pharmaceutical company that was previously focused on developing novel and proprietary therapies for the treatment of patients with prostate cancer. For more information, please visit

ESSA是一家制药公司，此前专注于开发治疗前列腺癌患者的新型和专利疗法。欲了解更多信息，请访问

www.essapharma.com

。

About XenoTherapeutics, Inc.

关于异种移植治疗公司

XenoTherapeutics Inc. is a

塞诺治疗公司是一家

Massachusetts

马萨诸塞州

-based 501(c)(3) research foundation focused on advancing xenotransplantation through scientific research, clinical development, and public education. For more information, please visit

基于501(c)(3)条款设立的研究基金会，专注于通过科学研究、临床开发和公共教育推动异种移植的发展。欲了解更多信息，请访问

www.xenotx.org

。

About XOMA Royalty Corporation

关于XOMA特许权公司

XOMA Royalty is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health. XOMA Royalty acquires the potential future economics associated with pre-commercial and commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies.

XOMA Royalty 是一家生物技术特许权收益聚合商，在帮助生物技术公司实现改善人类健康的目标方面发挥着独特的作用。XOMA Royalty 收购与已授权给制药或生物技术公司的临床前和商业化治疗候选药物相关的潜在未来经济利益。

When XOMA Royalty acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes. The Company has an extensive and growing portfolio of assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate).

当XOMA特许权收购未来经济权益时，卖方会获得非稀释性、无追索权的资金，这些资金可用于推进其内部药物候选品或用于一般公司用途。公司拥有广泛且不断增长的资产组合（资产定义为与潜在治疗候选药物进展相关的未来经济权益的接收权）。

For more information about the Company and its portfolio, please visit .

如需了解有关公司及其产品组合的更多信息，请访问。

www.xoma.com

or follow XOMA Royalty Corporation on LinkedIn.

或在 LinkedIn 上关注 XOMA 版权公司。

Forward Looking Statements

前瞻性声明

This communication, and any related oral statements, contains certain information which, as presented, constitutes 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995 and 'forward-looking information' within the meaning of applicable Canadian securities laws (collectively, 'forward-looking statements').

本沟通以及任何相关的口头陈述包含某些信息，这些信息在呈现时构成了《1995年私人证券诉讼改革法》所指的“前瞻性陈述”，以及适用的加拿大证券法所指的“前瞻性信息”（统称为“前瞻性陈述”）。

Forward-looking statements include, but are not limited to, statements that relate to future events and often address expected future business and financial performance, containing words such as 'anticipate', 'believe', 'plan', 'estimate', 'expect', and 'intend', statements that an action or event 'may', 'might', 'could', 'should', or 'will' be taken or occur, or other similar expressions and include, but are not limited to, statements regarding the proposed timing and completion of the Transaction; the amounts payable under the Transaction; the Company's application to the Supreme Court of .

前瞻性声明包括但不限于与未来事件相关的声明，通常涉及预期的未来业务和财务表现，包含诸如“预期”、“相信”、“计划”、“估计”、“预计”和“打算”等词语，声明中提到某个行动或事件“可能”、“或许”、“可以”、“应该”或“将”被采取或发生，或其他类似表述，并包括但不限于有关拟议交易的时间和完成情况的声明；根据该交易应付的金额；公司向高等法院提交的申请。

British Columbia

不列颠哥伦比亚省

for a reduction of capital and cash distribution prior to the closing of the Transaction; the timing and receipt of securityholder, regulatory and court approvals of the Transaction; the satisfaction of the conditions to the completion of the Transaction and other statements that are not statements of historical facts..

为了在交易完成前减少资本和现金分配；交易的时间安排及股东、监管机构和法院的批准；满足完成交易的条件及其他并非历史事实的陈述。

In this communication, these forward-looking statements are based on ESSA's current expectations, estimates and projections regarding, among other things, the expected date of closing of the Transaction and the potential benefits thereof, its business and industry, management's beliefs and certain assumptions made by ESSA, all of which are subject to change.

在此沟通中，这些前瞻性陈述基于ESSA当前的预期、估计和预测，涉及包括交易预计完成日期及其潜在收益、其业务和行业、管理层的信念以及ESSA所做的某些假设等内容，所有这些均可能发生变化。

Forward-looking statements are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of ESSA to control or predict, and which may cause ESSA's actual results, performance or achievements to be materially different from those expressed or implied thereby, including the consummation of the Transaction and the anticipated benefits thereof.

前瞻性声明受到各种已知和未知的风险和不确定性的影响，其中许多风险和不确定性是ESSA无法控制或预测的，这些因素可能导致ESSA的实际结果、表现或成就与声明中明示或暗示的内容存在重大差异，包括本次交易的完成及其预期收益。

Such statements reflect ESSA's current views with respect to future events, are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by ESSA as of the date of such statements, are inherently subject to significant medical, scientific, business, economic, competitive, regulatory, political and social uncertainties and contingencies.

此类声明反映了ESSA对未来的当前看法，涉及风险和不确定性，并且必然基于若干估计和假设，这些估计和假设在ESSA看来截至此类声明日期是合理的，但本质上受到重大的医学、科学、商业、经济、竞争、监管、政治和社会不确定因素及偶发事件的影响。

In making forward-looking statements, ESSA may make various material assumptions, including but not limited to (i) the completion of the Transaction on anticipated terms and timing, including obtaining required securityholder, regulatory and court approvals, and the satisfaction of other conditions to the completion of the Transaction; (ii) potential litigation relating to the Transaction that could be instituted by or against ESSA, Xeno, XOMA Royalty or their respective directors or officers, including the effects of any outcomes related thereto; (iii) the risk that disruptions from the Transaction will harm ESSA's business, in.

在做出前瞻性陈述时，ESSA可能会做出各种重大假设，包括但不限于：(i) 按预期条款和时间完成交易，包括获得所需的安全持有人、监管机构和法院的批准，以及满足交易完成的其他条件；(ii) 可能由ESSA、Xeno、XOMA Royalty或其各自董事或高管提起或针对他们的与交易相关的潜在诉讼，包括与此相关的任何结果的影响；(iii) 交易带来的中断可能损害ESSA业务的风险。

December 17, 2024

2024年12月17日

, under the heading 'Risk Factors', a copy of which is available on ESSA's profile on EDGAR at

在“风险因素”标题下，ESSA的EDGAR档案中可找到其副本，网址为

www.sec.gov

and on SEDAR+ at

并在SEDAR+上

www.sedarplus.ca

, and as otherwise disclosed from time to time on ESSA's EDGAR and SEDAR+ profiles; and (xvi) the risks and uncertainties that will be described in the proxy statement and management information circular for the Company's securityholders filed with the U.S. Securities and Exchange Commission (the 'SEC,' and such statement, the 'Proxy Statement') available from the sources indicated above..

，并且如ESSA在EDGAR和SEDAR+上的资料不时披露的其他信息；以及（十六）公司向美国证券交易委员会（“SEC”）提交的委托书和管理层信息通告中将描述的风险与不确定性（该声明称为“委托书”），可从上述来源获取。

These risks, as well as other risks associated with the Transaction, will be more fully discussed in the Proxy Statement. While the list of factors presented here is, and the list of factors to be presented in the Proxy Statement will be, considered representative, no such list should be considered a complete statement of all potential risks and uncertainties.

这些风险以及与本次交易相关的其他风险将在委托书中进行更全面的讨论。虽然此处列出的因素列表，以及将在委托书中列出的因素列表，被认为是具有代表性的，但任何此类列表都不应被视为对所有潜在风险和不确定性的完整陈述。

Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, business disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material impact on ESSA's financial condition, results of operations, credit rating or liquidity.

未列出的因素可能对前瞻性陈述的实现带来重大额外障碍。与前瞻性陈述中预期的结果存在重大差异的后果可能包括（但不限于）业务中断、运营问题、财务损失、对第三方的法律责任以及类似风险，其中任何一项都可能对ESSA的财务状况、经营结果、信用评级或流动性产生重大影响。

Forward-looking statements are made based on management's beliefs, estimates and opinions on the date that statements are made and ESSA undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change, except as may be required by applicable .

前瞻性声明是基于管理层在声明作出之日的信念、估计和意见作出的，ESSA 没有义务更新前瞻性声明，即使这些信念、估计和意见或其他情况发生变化，除非适用法律要求。

United States

美国

and Canadian securities laws. Readers are cautioned against attributing undue certainty to forward-looking statements.

并遵守加拿大证券法。读者应注意不要对前瞻性陈述赋予过度的确定性。

Important Additional Information and Where to Find It

重要的附加信息及其查找位置

In connection with the proposed Transaction between ESSA, Xeno and XOMA Royalty, ESSA will file with the SEC the Proxy Statement, the definitive version of which will be sent or provided to ESSA securityholders. ESSA may also file other documents with the SEC regarding the proposed Transaction. This document is not a substitute for the proxy statement or any other document which ESSA may file with the SEC.

关于ESSA、Xeno和XOMA Royalty之间拟议的交易，ESSA将向美国证券交易委员会（SEC）提交代理声明，其最终版本将发送或提供给ESSA的证券持有人。ESSA还可能就拟议的交易向SEC提交其他文件。本文件并非代理声明或ESSA可能向SEC提交的任何其他文件的替代品。

INVESTORS AND SECURITYHOLDERS ARE URGED TO READ THE PROXY STATEMENT AND ANY OTHER RELEVANT DOCUMENTS THAT ARE FILED OR WILL BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND RELATED MATTERS.

投资者和证券持有人被敦促仔细并全面阅读已提交或将会提交给美国证券交易委员会的委托书声明及任何其他相关文件，以及这些文件的任何修订或补充，因为它们包含或将会包含有关拟议交易及相关事项的重要信息。

Investors and securityholders may obtain free copies of the proxy statement (when it is available) and other documents that are filed or will be filed with the SEC by ESSA through the website maintained by the SEC at .

投资者和证券持有人可以通过美国证券交易委员会（SEC）维护的网站免费获取ESSA提交或将会提交给SEC的委托书声明（当其可用时）和其他文件。

www.sec.gov

, on SEDAR+ at

，在SEDAR+上于

www.sedarplus.ca

, ESSA's website at

，ESSA的网站在

www.essapharma.com

。

Participants in the Solicitation

征求意见的参与者

ESSA and certain of its directors and executive officers may be deemed to be participants in the solicitation of proxies from ESSA's shareholders in connection with the proposed Transaction. Additional information regarding the identity of the participants, including a description of their direct or indirect interests, by security holdings or otherwise, will be set forth in the proxy statement and other materials to be filed with the SEC in connection with the proposed Transaction (if and when they become available).

ESSA 及其某些董事和高级管理人员可能被视为在拟议交易中向 ESSA 的股东征求委托书的参与者。有关参与者身份的更多信息，包括他们通过持有证券或其他方式直接或间接利益的描述，将在与拟议交易相关的委托书声明和其他提交给美国证券交易委员会（SEC）的文件中列出（如果及当这些文件可用时）。

Information relating to the foregoing can also be found in ESSA's proxy statement for its 2025 annual meeting of shareholders, which was filed with the SEC on .

有关上述信息的详情，亦可参阅ESSA为其2025年股东周年大会提交给美国证券交易委员会的委托书声明。

January 22, 2025

2025年1月22日

(the 'Annual Meeting Proxy Statement'). To the extent holdings of securities by potential participants (or the identity of such participants) have changed since the information printed in the Annual Meeting Proxy Statement, such information has been or will be reflected on ESSA's Statements of Change in Ownership on Forms 3 and 4 filed with the SEC.

（“年度会议委托书”）。若潜在参与者的证券持有量（或此类参与者的身份）在年度会议委托书所载信息之后发生了变化，该等信息已或将在ESSA向美国证券交易委员会提交的3号和4号表格《所有权变动声明》中反映。

You may obtain free copies of these documents using the sources indicated above..

您可以使用上述来源获取这些文件的免费副本。

ESSA Contact Information:

ESSA联系方式：

David Wood

大卫·伍德

Chief Financial Officer, ESSA Pharma Inc.

ESSA制药公司首席财务官

T: 778-331-0962

电话：778-331-0962

错误：